Decitabine 化学構造
分子量: 228.21

高品質保証

カスタマーフィードバック(3)

MSDS

製品説明

  • Compare DNA Methyltransferase Inhibitors
    DNA Methyltransferase製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Decitabineは一種のDNA methylationの有効な阻害剤で、骨髄異形成症候群(MDS)を治療することに使用されます。
ターゲット DNA methyltransferase (HL-60) DNA methyltransferase (KG1a)
IC50 100 ng/mL 1 ng/mL [1]
In vitro試験 Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
Eca109 NVexXXhITnWwY4Tpc44hSXO|YYm= MX6wMlXDqM7:TR?= NIK3N5IzPCCq MUf3ZZRmeg>? NIX1N4Vud2S3bHH0[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDNRWdGNUFibXXtZoVzew>? M1LuVVI2OTJ|MEiy
Eca109 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXOwMlUwOi53L{Wg{txO NI[0T|QzPC92OD:3NkBp M4nRWJdifGW{ NVnRdoN6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NXT3V|VyOjVzMkOwPFI>
Eca109 NH63U3ZHfW6ldHnvckBCe3OjeR?= NGHSSIgxNjYEoN88US=> NXfPOmcyPi9zMj:yOEBp NXrhNolVf2G2ZYK= NVO0NItJcW6qaXLpeJMh[2WubDDtbYdz[XSrb39CpC=> NUjPS3k{OjVzMkOwPFI>
Eca109 NX;TT4gzTnWwY4Tpc44hSXO|YYm= M{HOelAvPcLizszN M1PxU|I1KGh? NIHIO|F4[XSnch?= M1KxeIlvcGmkaYTzJINmdGxiaX72ZZNqd25? NIizUFMzPTF{M{C4Ni=>
Eca109 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrBNE42yqEQvF2= NF7sNGszPCCq M1OxeZdifGW{ M4LFcIlv\HWlZYOgS|IwVSCjcoLld5QhcW5idHjlJINmdGxiY4njcIU> M1rmOlI2OTJ|MEiy
Eca109 NX7z[XJjTnWwY4Tpc44hSXO|YYm= Mn3VNE42NzFizszN NXrRZ41COjRiaB?= NXnnS4d2f2G2ZYK= MV7k[YNz\WG|ZYOg[ZhxemW|c3nvckBw\iCQRj5OvmIzKGGwZDDNUXAz MWeyOVEzOzB6Mh?=
SW1116  NY\1OGVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvPNE42NzFxMj:1JO69VQ>? M{fWeVQ5KGh? M17w[GROW09? NUTVdlRx\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>? MXKyOFg4PDJ6Nh?=
LOVO NWO3NY0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF23SmwxNjVxMT:yM|Uh|ryP NUDVPJZCPDhiaB?= M2LLeGROW09? NVjJRotU\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>? MXSyOFg4PDJ6Nh?=
SW1116  NHHuZZZHfW6ldHnvckBCe3OjeR?= M1vmdVExKM7:TR?= MU[0PEBp MX7EUXNQ M3TxeIlv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>? Mn;MNlQ5PzR{OE[=
LOVO MkPVSpVv[3Srb36gRZN{[Xl? NHjBTGoyOCEQvF2= M{n3fVQ5KGh? M1T6V2ROW09? NVfLcWlncW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk MlnwNlQ5PzR{OE[=
SW1116  MlG5RZBweHSxc3nzJGF{e2G7 NIfRdlEyOCEQvF2= NIPjUnk1QCCq Mle2SG1UVw>? NFqyXJBmdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM> M1PDRVI1QDd2Mki2
LOVO M{XOOWFxd3C2b4Ppd{BCe3OjeR?= M4XXT|ExKM7:TR?= MkC4OFghcA>? NH;0[WpFVVOR MnP1[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz NFnkSHozPDh5NEK4Oi=>
RPMI-8226 NUXLR2p1SXCxcITvd4l{KEG|c3H5 MXuxM|Ih|ryP NGPWd|k1QC95Mj:5OkBp NIfscFlFVVOR NVz2RmU{cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NGnwZ|QzPDh|M{GwPC=>
OPM-2  MWLBdI9xfG:|aYOgRZN{[Xl? MUWxM|Ih|ryP M1HoVVczNzl4L{GyNEBp MYDEUXNQ NIm3OW1qdmS3Y3XzJINmdGxiYYDvdJRwe2m| MXSyOFg{OzFyOB?=
JJN3  MkDGRZBweHSxc3nzJGF{e2G7 M2Ow[lAvPS9zIN88US=> NGK1OpAzPC92ODDo MU\EUXNQ MmqxbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NFTS[oUzPDh|M{GwPC=>
NCI-H929  MYnBdI9xfG:|aYOgRZN{[Xl? NFjNZmoyNzJizszN NGjC[m44Oi97Nj:xNlAhcA>? MWXEUXNQ M1TLb4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MofLNlQ5OzNzMEi=
RPMI-8226 NGrEeINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7v[WQzOS9{IN88US=> NH;NZ3czPC92OD:3NkBp MXHEUXNQ MYPh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? MoLoNlQ5OzNzMEi=
OPM-2  NFzGSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYKxM|Ih|ryP MnPCNlQwPDhxN{KgbC=> NH3Lb|dFVVOR Ml3jZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? NI\pZ|YzPDh|M{GwPC=>
JJN3  NUL0PGRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXlNE42NzFizszN NYi0WIxjOjRxNEivO|IhcA>? NWnBOWwyTE2VTx?= M4DlNYFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 MkG0NlQ5OzNzMEi=
NCI-H929  NV73cYZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TY[VEwOiEQvF2= NXj1OmRJOjRxNEivO|IhcA>? M1\MO2ROW09? MWrh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? NILidGEzPDh|M{GwPC=>
HeLa MmPhT4lv[XOnIFHzd4F6 MWfLbV0yODBy4pETOVAxOCEQvF2g[o9zKGiHTmSx M4LkTVI1PzhyMEm4
HeLa M{HM[WtqdmG|ZTDBd5NigQ>? Mn71T4k:PS54INMxJFAvPSEQvF2g[o9zKGiHTmSy MY[yOFc5ODB7OB?=
HeLa MoLvT4lv[XOnIFHzd4F6 M4m1S2tqRTJzLk[gxtEhOy5yIN88UUBnd3JiaFPOWFE> M1zJOVI1PzhyMEm4
HeLa M4n4WmtqdmG|ZTDBd5NigQ>? MofPT4k:OTRwNDFCtUA1NjZizszNJIZweiCqQ17UNy=> MViyOFc5ODB7OB?=
NB4 NHrGTG9HfW6ldHnvckBCe3OjeR?= MVeyMlUwPS95LkWvNVAh|ryP NW\ZcHVFOjRiaB?= MmXVSG1UVw>? NH\YRm5qdmO{ZXHz[YEhfGinIHX4dJJme3Orb36gc4YheHKnY4Xyd49zKG2rUj2xNlVi NHrhWmczPDR6NEi3NC=>
CD4+ CD25− T  M{D6fmZ2dmO2aX;uJGF{e2G7 Mkn4NU82KM7:TR?= NVywfpR3emWmdXPlV{BodG:kYXygSG5CKG2ndHj5cIF1cW:w NXvjW5NHOjR2N{[zOlA>
BV-173 M1\sWGFxd3C2b4Ppd{BCe3OjeR?= M37ifVAvOjVxMD61M|AvPzVxMTFOwG0> Mom4OFgwPzJxOU[gbC=> NGDLc3fDqFCEUx?= M2jNWolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MmnQNlQ1OjN4MUO=
ML-1 NYHCNWJxSXCxcITvd4l{KEG|c3H5 NXW2bo1[OC5{NT:wMlUwOC55NT:xJO69VQ>? NXrCfZJ4PDhxN{KvPVYhcA>? MVJCpHBDWw>? Mn;sbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy MUKyOFQzOzZzMx?=
HL-60 MWrBdI9xfG:|aYOgRZN{[Xl? M2[4SFAvOjVxMD61M|AvPzVxMTFOwG0> NYm0[Zd6PDhxN{KvPVYhcA>? MVdCpHBDWw>? Mn;BbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NVrLSZRQOjR2MkO2NVM>
KG-1a NH;xOFVCeG:ydH;zbZMhSXO|YYm= MmfWNE4zPS9yLkWvNE44PS9zIN88US=> MU[0PE84Oi97NjDo NYfaN3U1yqCSQmO= MXHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= MUCyOFQzOzZzMx?=
BV-173 Mo\VSpVv[3Srb36gRZN{[Xl? MnvCNlUxNzVyMH7N M2DUTVQ5KGh? NVvCSmxkyqCSQmO= MVfpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? MoXCNlQ1OjN4MUO=
CEM NVnQVot1TnWwY4Tpc44hSXO|YYm= M3LIXFI2OC93MEDuUS=> Mn3KOFghcA>? NXL3UJNuyqCSQmO= MW\pcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NHL5e5QzPDR{M{[xNy=>
HL-60 MoHiSpVv[3Srb36gRZN{[Xl? MUKyOVAwPTBybl2= NVG2Xm4yPDhiaB?= NYLmXZpWyqCSQmO= M3OwdYlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MnjaNlQ1OjN4MUO=
ML-1 MWPGeY5kfGmxbjDBd5NigQ>? MYOyOVAwPTBybl2= NImwOnM1QCCq MXNCpHBDWw>? NWPBS41QcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl NWHPVHFFOjR2MkO2NVM>
DLD-1 MYfGeY5kfGmxbjDBd5NigQ>? M17Ed|I2OC93MEDuUS=> MXq0PEBp NFzwS4fDqFCEUx?= NHvJS|hldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MoTwNlQ1OjN4MUO=
HCT-116 MVLGeY5kfGmxbjDBd5NigQ>? M3PqWlI2OC93MEDuUS=> NYrxfYl{PDhiaB?= NVSxR3V7yqCSQmO= MXfkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm M1HtNlI1PDJ|NkGz
U937-A/E-9/14/18  M1jnV2Fxd3C2b4Ppd{BCe3OjeR?= MknNNE4xOS9yLkGvNU8yOCEQvF2= M4PSSFQ5KGh? MoD2bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MU[yOFMxODR3Nh?=
HT29 M4rKWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXO4eYNvPzJiaB?= MYrJR|UxRTF2MEFCtVE4QSEQvF2= NHf0fWYzPDF5MkC2NS=>
SW48 NFyxbmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY[3NkBp MXrJR|UxRTF3LkNCtVYvOiEQvF2= MX6yOFE4OjB4MR?=
HCT116 M1jkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYW3NkBp MV7JR|UxRTFwN9MxNE41KM7:TR?= MW[yOFE4OjB4MR?=
HepG2 NWn3bmZLTnWwY4Tpc44hSXO|YYm= MU[wMlUwOSEQvF2= M3[weVI1KGh? MoDJSG1UVw>? MWT1dE1z\We3bHH0[YQhfGinIILlcIF1cX[nIF;DWG4zKG2UTlGgZY5lKHC{b4TlbY4h\XiycnXzd4lwdg>? NWPCRZY2OjRzNE[4O|Q>
LS174T MXvGeY5kfGmxbjDBd5NigQ>? Mk\RNE42NzFizszN NUSyTlJKOjRiaB?= MWnEUXNQ MUXs[YFlKHSxIHHuJIlv[3KnYYPlJI9nKE:FVF6yJIxmfmWucx?= NYTad3JFOjRzNE[4O|Q>
HepG2 NWSyN4ppSXCxcITvd4l{KEG|c3H5 MlfyNU8yOC9zMECg{txO NVnJbo5sPyCm M1TEZWROW09? NVfKSop2cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MVuyOFE1Pjh5NB?=
LS174T NWrvTo1sSXCxcITvd4l{KEG|c3H5 NXXFfHM1OS9zMD:xNFAh|ryP MnLjO{Bl MmXqSG1UVw>? MWrpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NHTSeHozPDF2Nki3OC=>
QBC-939 MnTWRZBweHSxc3nzJGF{e2G7 NXHWdpAyOS9zMD:xNFAh|ryP MWG3JIQ> M3[2VGROW09? NEXVbZRqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MXqyOFE1Pjh5NB?=
U251 NV33XHNGSXCxcITvd4l{KEG|c3H5 NXz1ZWh{OS9zMD:xNFAh|ryP MVy3JIQ> M1jsS2ROW09? NX3qdGxtcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHfYOHAzPDF2Nki3OC=>
HL-60 NXTscmx2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7EcVJ7OSEQvF2= NYXhbFFlPDhiaB?= MoDibY5kemWjc3XzJGczNXCqYYPlJINmdGxiZoLhZ5Rqd25? MnLLNlQxODB|MkS=
MDA‑MB‑453 MUHGeY5kfGmxbjDBd5NigQ>? NWjwWm9POC5{L{Gg{txO NHmxOnE4OiCq NHHXcFVk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> NVjJWG5ZOjN6NESyNlg>
HCC1569 NGLLOYRHfW6ldHnvckBCe3OjeR?= NHrnXVUxNjJxMTFOwG0> MoDkO|IhcA>? MYTjZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= NXX6fmZXOjN6NESyNlg>
BT‑474 MmHqSpVv[3Srb36gRZN{[Xl? M4K2V|AvOi9zIN88US=> MVy3NkBp NIPs[3hk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> MV:yN|g1PDJ{OB?=
AGS MYTBdI9xfG:|aYOgRZN{[Xl? NEGyZZc2NzFyL{KwM|UxKM7:TR?= NV[3dm1TPDkEoHlCpC=> MXnEUXNQ NITXNZZqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>? MVWyN|U5Ojd6NB?=
A549 NI\xfXZCeG:ydH;zbZMhSXO|YYm= MXu1M|ExNzJyL{WwJO69VQ>? NIfDVGk1QMLiaNMg Ml7ZSG1UVw>? NVq5WVBKcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB? NHXSXlEzOzV6Mke4OC=>
AGS  MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LpV|UwOTBxMkCvOVAh|ryP NXzHSphuPDkEoHlCpC=> NYr0[|F[TE2VTx?= NIr6fIVqdmS3Y3XzJGczN01icHjhd4Uh[XK{ZYP0xsA> MWWyN|U5Ojd6NB?=
Kasumi-1 NHSxSXJCeG:ydH;zbZMhSXO|YYm= NYLkfpJuOC53IN88US=> Mn;0OFjDqGkEoB?= NIizW|ll\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> NIHyT4YzOzR7M{O0PC=>
OCI-AML3 MoDtRZBweHSxc3nzJGF{e2G7 M4frc|IvPSEQvF2= M4rFZ|Q5yqCqwrC= Mo[1[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= MV:yN|Q6OzN2OB?=
MV4-11 NXi3W3lUSXCxcITvd4l{KEG|c3H5 M33zblIvPSEQvF2= NXXxNYRMPDkEoHlCpC=> NH25coZl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> MmmyNlM1QTN|NEi=
NK  M1zYfWN6fG:2b4jpeJkhSXO|YYm= MWGwMlAzNTJyIN88US=> NULHZnJ5PSCm NUW1fpJR\GWlcnXhd4V{KHSqZTDjfZRwdHm2aXOgZYN1cX[rdImgc4YhVktiY3XscJMh[XRiaX70[ZJu\WSrYYTlJINwdmOnboTyZZRqd26|IILld5VtfGmwZzDpckBiKFVvc3jhdIVlKGSxc3ZihLNz\XOyb37z[UBkfXK4ZR?= NFzVSnUzOzN{OEC4PC=>
NK  NVz1fJptSXCxcITvd4l{KEG|c3H5 NHLEUpkxNjB{LUKwJO69VQ>? M1j4SlUh\A>? M37yS4Rm[3KnYYPlJG5MKGOnbHygdJJwdGmoZYLheIlwdiCjbnSgeoli[mmuaYT5JIF{KHSqZTDjc45k\W62cnH0bY9vKGmwY4LlZZNm\A>? M1HTRlI{OzJ6MEi4
NK  NHPLTplHfW6ldHnvckBCe3OjeR?= NFX1WmgxNjBzLUKwJO69VQ>? MoTQOUBl MWrjZZV{\XNiaInwc41mfGi7bHH0bY9vKG:oIF7LJINmdGy|IHnuJIEh\G:|ZfMAl5Jme3CxboPl NIPFWYIzOzN{OEC4PC=>
MOLT4/DNR MYLGeY5kfGmxbjDBd5NigQ>? MmjBOUDPxE1? Ml;JOEBl MoTadoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44> M4TreVI{ODZyNUew
Jurkat/DOX NYrtWY81TnWwY4Tpc44hSXO|YYm= MV61JO69VQ>? NGnZOHo1KGR? NIHOS2Jz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? NYDyVHVmOjNyNkC1O|A>
MOLT4/DNR MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzlPIE2KM7:TR?= MUS0JIQ> MnX6doVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC|ZX7zbZRqfmm2eR?= MnHvNlMxPjB3N{C=
Jurkat/DOX NGX0OlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLoWmJsPSEQvF2= NGTNSGg1KGR? NF34UWFz\WS3Y3XzJJRp\SCLQ{WwxsB3[Wy3ZTDmc5Ih\GG3bn;yeYJq[2mwIIPlcpNqfGm4aYT5 MYCyN|A3ODV5MB?=
ccRCC  NIT4SFZCeG:ydH;zbZMhSXO|YYm= MYSwMlAyNTFyzszN MX23NkBp MlHVSG1UVw>? NWfEVGQ6cGG|IH3pcolu[WxiZX\m[YN1KG:wIHPlcIwheHKxbHnm[ZJifGmxbh?= NFv5TIszOjh{NkS2Oy=>
TNBC  NF7jPFZCeG:ydH;zbZMhSXO|YYm= NUTtRY5kOC5yMT2xNO69VQ>? MkjXO|IhcA>? MUjEUXNQ MXzoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v NXX3W5NUOjJ6Mk[0Olc>
A498 MVHBdI9xfG:|aYOgRZN{[Xl? NUTlPGY4OC5yMT2xNO69VQ>? NF3LfnM4OiCq MXjEUXNQ M{PB[Ylv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> MYOyNlgzPjR4Nx?=
KIJ265T NIjuUmZCeG:ydH;zbZMhSXO|YYm= NH7UdHQxNjBzLUGw{txO NGXO[Yk4OiCq MVLEUXNQ MmSzbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> M3GzRlIzQDJ4NE[3
MDA-231 MVzBdI9xfG:|aYOgRZN{[Xl? NY[1[plEOC5yMT2xNO69VQ>? MnjzO|IhcA>? NHLYdnFFVVOR MYHpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu NFT5VWYzOjh{NkS2Oy=>
BT-20 NHS4UWJCeG:ydH;zbZMhSXO|YYm= MXiwMlAyNTFyzszN M3HwSlczKGh? M2rLTWROW09? MVLpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu MXiyNlgzPjR4Nx?=
U937 MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDzNmE2NTJyIN88US=> NUTzOoVVOjRxNEivO|IhcA>? MkHLbY5lfWOnczDhJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIlvKGFiY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MUCyNlc3PzB{MR?=
HL60 NYDLUY1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUm1MVIxKM7:TR?= NIjvXlQzPC92OD:3NkBp NVTiTIpFcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NGrYd3YzOjd4N{CyNS=>
U937 M1jWbGFxd3C2b4Ppd{BCe3OjeR?= NUPkSVl1OTVizszN NWPpbWdWOjRxNEivO|IhcA>? MX;pcoR2[2W|IHPlcIwh[XCxcITvd4l{ NUO1VVI1OjJ5NkewNlE>
HL60 NHGx[JZCeG:ydH;zbZMhSXO|YYm= NGjwR2MyPSEQvF2= NH\3[4kzPC92OD:3NkBp NGf6O|RqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MoS4NlI4PjdyMkG=
LS411N  NFTGbHBCeG:ydH;zbZMhSXO|YYm= MVKwMlUh|ryP NVP0cXVbPzJiaB?= NX3CSnZwcW6lcnXhd4V{KE[jczDtVm5CKGyndnXs NYixPYEyOjJ2NkG2PVU>
MDA-MB-231 M4Pp[GFxd3C2b4Ppd{BCe3OjeR?= M1nJZlExKM7:TR?= M2\oWVQ5KGh? NV7Well1emWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1TBd|IyQDh5Nkm3
MCF-7  NYX0ZXZZSXCxcITvd4l{KEG|c3H5 Ml;qNVAh|ryP MYi0PEBp M2f3OpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NEHrRlkzOTh6N{[5Oy=>
A375 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXqwMlUh|ryP MUGxM|UwQCCm MojjbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? M4DzUlIyPzl4NkKy
SKMEL1 M2XvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXCUnYxNjVizszN M3\je|EwPS96IHS= M2\i[IlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NILxSW4zOTd7Nk[yNi=>
SKMEL3 NHjrSXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIi0RZMxNjVizszN NETF[YwyNzVxODDk NY\C[|RScW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= M37tNFIyPzl4NkKy
SKMEL28 M4W5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[wMlUh|ryP NVPtUlZ7OS93L{ig[C=> NV7Zb|hucW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NV\MZ2J4OjF5OU[2NlI>
MeWo NYCxTVJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGWxcIsxNjVizszN MlHpNU82NzhiZB?= MoTEbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? Mlr5NlE4QTZ4MkK=
B16 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDqc5ExNjVizszN NXnWOXF5OS93L{ig[C=> MUPpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? MYOyNVc6PjZ{Mh?=
Ly 1 NHfvelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYiyOEBp NGO5OmVKSzVyPUeuN{DPxE1? M2TzWVIyPzd{MES5
Ly 7 MnLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rncFI1KGh? NEjTWndKSzVyPUGwMlch|ryP MoXCNlE4PzJyNEm=
Su-DHL6 M2XVb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlW3NlQhcA>? NVn4[3BZUUN3MP-8olIxKM7:TR?= M2\R[FIyPzd{MES5
Ly 10 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjKNlQhcA>? NELLXZpKSzVy78{eNlAh|ryP NGLIcWMzOTd5MkC0PS=>
RIVA MnvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoD3NlQhcA>? MWfJR|Ux97zgMkCg{txO NVXyW2ptOjF5N{KwOFk>
Su-DHL2 M4[3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlT1NlQhcA>? NF;tTXhKSzVy78{eNlAh|ryP NXLrWHJ3OjF5N{KwOFk>
Ly 1 MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13iUFQ5KGh? NHXv[XFKSzVyPUCuN|Qh|ryP MUeyNVc4OjB2OR?=
Ly 7 MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWS0PEBp NIHWPXFKSzVyPUCuNFI2KM7:TR?= MV2yNVc4OjB2OR?=
Su-DHL6 NFnPRmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkOxOFghcA>? MYnJR|Ux97zgMkCg{txO M3zM[|IyPzd{MES5
Ly 10 M2HaR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXm0PEBp NF2zeXZKSzVyPUGuPEDPxE1? MmD4NlE4PzJyNEm=
RIVA NX3GVI5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjLTJdpPDhiaB?= M{XQUGlEPTExvK6yNEDPxE1? MoTXNlE4PzJyNEm=
Su-DHL2 NVy0UYN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;afmhHPDhiaB?= M{HMXWlEPTB;MUeuOEDPxE1? NFzGbJkzOTd5MkC0PS=>
Ly 1 NFHJbGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoexO|IhcA>? M{PSVGlEPTB;MD6wNUDPxE1? M{n6Z|IyPzd{MES5
Ly 7 NET6VY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3WO|IhcA>? M4jJbWlEPTB;MD6wNVgh|ryP NVP3U4F[OjF5N{KwOFk>
Su-DHL6 M4TUdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PqOVczKGh? NWjoWHZzUUN3ME2xMlYh|ryP MnrENlE4PzJyNEm=
Ly 10 NEXOVlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrhcpA4OiCq M4i1V2lEPTB;MT6yJO69VQ>? MnfFNlE4PzJyNEm=
RIVA MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInOTZM4OiCq M1fmeGlEPTExvK6yNEDPxE1? M3HZRlIyPzd{MES5
Su-DHL2 M2rh[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1O1eVczKGh? M{nFWWlEPTB;MUGuNkDPxE1? NHP4W3czOTd5MkC0PS=>

... Click to View More Cell Line Experimental Data

In vivo試験 In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]
臨床試験 Decitabine is currently in Phase I clinical trials in patients with Higher-risk MDS and MDS/AML Receiving Allogeneic Stem Cell Transplantation.
特集

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

DNA synthesis assay The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.

細胞アッセイ: [1]

細胞株 HL-60 and KG1a
濃度 0-500 nM
反応時間 96 hours
実験の流れ For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.

動物実験: [2]

動物モデル KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
製剤 Decitabine is dissolved in sterile PBS .
投薬量 ≤2.5 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Decitabine SDF
分子量 228.21
化学式

C8H12N4O4

CAS No. 2353-33-5
保管 3年-20℃
2年-80℃in solvent
別名 Deoxycytidine
溶解度 (25°C) * In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol <1 mg/mL
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 4-amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one

文献中の引用 (6)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related DNAメチルトランスフェラーゼ 阻害剤

最近チェックしたアイテム

Tags: Decitabineを買う | Decitabine供給者 | Decitabineを購入する | Decitabine費用 | Decitabine生産者 | オーダーDecitabine | Decitabine代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ